M2 Pharma - Policy and Regulations

Policy & Regulation

Catalyst Pharmaceutical Partners announces filing of provisional patent application for GABA for Tourette Syndrome in the US

10 February 2012 - Biopharmaceutical company Catalyst Pharmaceutical Partners Inc (Nasdaq:CPRX) said on Thursday that it has filed a provisional patent application with the United States Patent and Trademark Office for GABA aminotransferase inhibitors for Tourette Syndrome treatment.

Thro...

You must be logged in to view the whole article.
Click here if you require signing up

Related Headlines

Abbott receives approval for HUMIRA from the United States Food and Drug Administration

Boston Scientific Corporation gets FDA approval for world’s first and only commercially available S-ICD System for patients at risk of sudden cardiac arrest

Catalyst Pharmaceutical Partners announces filing of provisional patent application for GABA for Tourette Syndrome in the US

FDA lifts partial clinical hold on Idenix's HCV nucleotide inhibitor IDX184

ODAC to assess Talon's Marqibo on 21 March

Boston Scientific wins CE Mark for Infinion 16 percutaneous lead

Merck receives FDA approval for JANUMET XR for Type 2 diabetes

Neptune Technologies agrees to stay of litigation in patent lawsuit

Janssen's Zytiga fails to secure NICE recommendation

FDA to grant Priority Review status to ThromboGenics' ocriplasmin

FDA committee to discuss Arena Pharma weight-loss drug in Q2 2012

German Supreme Court upholds IntraOp patent

Navidea Biopharmaceuticals gets CHMP's go-ahead to file MAA for Lymphoseek

Horizon Medical Services gets Canadian regulatory nod for Hitachi SCENARIA 64-Slice CT

NLT SPINE gets FDA approval for PROW FUSION device